Medine.co.uk

Refresh Ophthalmic

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Liquiflim® Tears Preservative Free or Refresh Ophthalmic TM

2.    QUALITATIVE AND QUANTITATIVE COMPOSITION

Polyvinyl alcohol 1.4% w/v.

3.    PHARMACEUTICAL FORM

Eye drops, solution

4    CLINICAL PARTICULARS

4.1.    Therapeutic Indications

Symptomatic relief of dry eye and symptomatic relief of eye irritation associated with deficient tear production.

4.2    Posology and method of administration

Ensure container is intact. Twist off tab and apply eyedrops.

Dosage schedule: Apply one or two drops in each eye as needed, or as directed. No special dosage for the elderly or for children.

Route of administration: Ocular instillation.

4.3    Contraindications

Hypersensitivity to the active substance polyvinyl alcohol or any of the other excipients.

4.4    Special warnings and precautions for use

If irritation, pain, redness and changes in vision occur or worsen, treatment should be discontinued and a new assessment considered.

To avoid contamination the dropper tip should not be allowed to touch the eye or any other surface.

Contact lenses should be removed before each application and may be reinserted after 15 minutes.

Concomitant ocular medication should be administered 15 minutes prior to the instillation of Liquifilm Tears Preservative Free or Refresh Ophthalmic.

4.5    Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

4.6    Pregnancy and lactation

The constituents of Liquifilm Tears Preservative Free or Refresh Ophthalmic have been used as pharmaceutical agents for many years with no untoward effects. No special precautions are necessary for the use of Liquifilm Tears Preservative Free or Refresh Ophthalmic in pregnancy and lactation.

4.7    Effects on ability to drive and use machines

Liquifilm Tears Preservative Free or Refresh Ophthalmic has minor or moderate influence on the ability to drive and use machines as it may cause transient blurring of vision. Do not drive or use hazardous machinery unless vision is clear.

4.8    Undesirable effects

Liquifilm Tears Preservative Free or Refresh Ophthalmic may cause transient stinging or irritation on instillation.

The frequency of the following undesirable effects is not known (cannot be estimated from the available data).

Eye disorders

•    Eye irritation

•    Eye pain

•    Ocular hyperaemia

•    Vision blurred

•    Eye pruritus

•    Foreign body sensation

•    Eye discharge

•    Hypersensitivity

4.9    Overdose

No case of overdose has been reported. Accidental overdose will not present any hazard.

5    PHARMACOLOGICAL PROPERTIES

5.1    Pharmacodynamic properties

Liquiflim® Tears Preservative Free/REFRESH OPHTHALMIC™ exerts a mechanical, not a pharmacological action. The viscosity enhancing agent is polyvinyl alcohol and the lubricating-enhancing agent is povidone.

5.2    Pharmacokinetic properties

Not applicable.

5.3    Preclinical safety data

The constituents of Liquiflim® Tears Preservative Free/REFRESH OPHTHALMICTM have been used safely in pharmaceutical products for many years. Topical administration in animals studies showed no untoward effects.

6    PHARMACEUTICAL PARTICULARS

6.1    List of excipients

Povidone Sodium chloride

Sodium hydroxide or hydrochloric acid (to adjust pH) Purified water

6.2    Incompatibilities

None known.

6.3    Shelf-Life

24 months (unopened).

Do not store opened container.

6.4 Special Precautions for Storage

Store at 25 °C or below.

6.5 Nature and Content of Container

Low density polyethylene unit dose vials containing 0.4 ml of Liquifilm® Tears Preservative Free/REFRESH OPHTHALMIC™.

Cartons contain 2, 5, 10, 15, 30 or 50 units per pack.

6.6 Instruction for Use, Handling and Disposal

Ensure container is intact. Twist off tab and apply eyedrops.

7    MARKETING AUTHORISATION HOLDER

Allergan Ltd

Marlow International

The Parkway

Marlow

Bucks

SL7 1YL

UK

8. MARKETING AUTHORISATION NUMBER

PL 00426/0063

9    DATE OF FIRST AUTHORISATION/RENEWAL OF THE

AUTHORISATION 10/12/2007

10 DATE OF REVISION OF THE TEXT

23/07/2008